- Home
- ATRA vs CGTX Comparison
ATRA vs CGTX Comparison
Compare ATRA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATRA | CGTX |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.4M | 132.4M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ATRA | CGTX |
|---|---|---|
| Price | $4.55 | $1.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $6.00 | $3.33 |
| AVG Volume (30 Days) | 610.3K | ★ 938.8K |
| Earning Date | 03-06-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.97 | N/A |
| Revenue | ★ $151,930,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.31 | ★ N/A |
| Revenue Growth | ★ 51.27 | N/A |
| 52 Week Low | $4.25 | $0.22 |
| 52 Week High | $19.15 | $3.83 |
Technical Indicators
Market Signals| Indicator | ATRA | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 23.81 | 49.06 |
| Support Level | $4.25 | $1.37 |
| Resistance Level | $5.19 | $1.50 |
| Average True Range (ATR) | 1.63 | 0.09 |
| MACD | -1.54 | 0.01 |
| Stochastic Oscillator | 2.07 | 56.25 |
Price Performance
Historical ComparisonAbout ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.